Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide
gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the …

Objectives The aim was to evaluate the efficacy, defined as achieving target serum urate <6.0
mg/dl, and safety of urate-lowering therapies (ULTs) for people with gout and chronic …

Objective. To determine the relationship between gout flare rate and self-categorization into
remission, low disease activity (LDA), and patient acceptable symptom state (PASS). …

… Author links open overlay panel Ana Beatriz Vargas-Santos MD 1 , Tuhina Neogi MD, PhD,
… -B*5801 allele, and the risk is highest in the first 6 months of use.45, 46, 47, 48, 49, 50, 51 …

… Vargas-Santos has received speaking fees (less than $10,000) from AstraZeneca. Dr.
Cimmino has received consulting fees, speaking fees, and/or honoraria (less than $10,000) from …

Importance Clinicians are often cautious about use of allopurinol in patients with gout when
renal function declines. Objective To assess the association of allopurinol use in gout with …

Objective The language currently used to describe gout lacks standardization. The aim of
this project was to develop a consensus statement on the labels and definitions used to …

Objective There is a lack of standardisation in the terminology used to describe gout. The
aim of this project was to develop a consensus statement describing the recommended …

… Ana Beatriz Vargas-Santos,1 … Vargas- Santos had full access to all of the data in the
study and takes responsibility for the integrity of the data and the accuracy of the data analysis. …

Objective To perform external validation of a provisional definition of disease flare in
patients with gout. Methods Five hundred nine patients with gout were enrolled in a cross‐sectional …